Puma Biotechnology PBYI Stock
Puma Biotechnology Price Chart
Puma Biotechnology PBYI Financial and Trading Overview
| Puma Biotechnology stock price | 9.24 USD |
| Previous Close | 9.11 USD |
| Open | 9.26 USD |
| Bid | 6.78 USD x 200 |
| Ask | 11.75 USD x 200 |
| Day's Range | 9.08 - 9.48 USD |
| 52 Week Range | 4.3 - 9.51 USD |
| Volume | 241.8K USD |
| Avg. Volume | 318.21K USD |
| Market Cap | 476.97M USD |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | 18.117647 |
| EPS (TTM) | 0.51 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6 USD |
PBYI Valuation Measures
| Enterprise Value | 387.88M USD |
| Trailing P/E | 18.117647 |
| Forward P/E | 26.4 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.0626237 |
| Price/Book (mrq) | 3.4083364 |
| Enterprise Value/Revenue | 1.677 |
| Enterprise Value/EBITDA | 9.669 |
Trading Information
Puma Biotechnology Stock Price History
| Beta (5Y Monthly) | 1.22 |
| 52-Week Change | 85.17% |
| S&P500 52-Week Change | 18.67% |
| 52 Week High | 9.51 USD |
| 52 Week Low | 4.3 USD |
| 50-Day Moving Average | 8.16 USD |
| 200-Day Moving Average | 6.85 USD |
PBYI Share Statistics
| Avg. Volume (3 month) | 318.21K USD |
| Avg. Daily Volume (10-Days) | 304.4K USD |
| Shares Outstanding | 51.62M |
| Float | 39.62M |
| Short Ratio | 12.16 |
| % Held by Insiders | 15.27% |
| % Held by Institutions | 75.57% |
| Shares Short | 4.13M |
| Short % of Float | 9.47% |
| Short % of Shares Outstanding | 8.06% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 11.55% |
| Operating Margin (ttm) | 13.42% |
| Gross Margin | 74.83% |
| EBITDA Margin | 17.34% |
Management Effectiveness
| Return on Assets (ttm) | 9.81% |
| Return on Equity (ttm) | 21.96% |
Income Statement
| Revenue (ttm) | 231.24M USD |
| Revenue Per Share (ttm) | 4.57 USD |
| Quarterly Revenue Growth (yoy) | 7.79% |
| Gross Profit (ttm) | 173.04M USD |
| EBITDA | 40.12M USD |
| Net Income Avi to Common (ttm) | 26.72M USD |
| Diluted EPS (ttm) | 0.51 |
| Quarterly Earnings Growth (yoy) | 39.90% |
Balance Sheet
| Total Cash (mrq) | 93.9M USD |
| Total Cash Per Share (mrq) | 1.82 USD |
| Total Debt (mrq) | 4.82M USD |
| Total Debt/Equity (mrq) | 3.48 USD |
| Current Ratio (mrq) | 2.912 |
| Book Value Per Share (mrq) | 2.711 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 41.15M USD |
| Levered Free Cash Flow (ttm) | 32.47M USD |
Profile of Puma Biotechnology
| Country | United States |
| State | CA |
| City | Los Angeles |
| Address | 10880 Wilshire Boulevard |
| ZIP | 90024 |
| Phone | 424 248 6500 |
| Website | https://www.pumabiotechnology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 179 |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Q&A For Puma Biotechnology Stock
What is a current PBYI stock price?
Puma Biotechnology PBYI stock price today per share is 9.24 USD.
How to purchase Puma Biotechnology stock?
You can buy PBYI shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Puma Biotechnology?
The stock symbol or ticker of Puma Biotechnology is PBYI.
Which industry does the Puma Biotechnology company belong to?
The Puma Biotechnology industry is Biotechnology.
How many shares does Puma Biotechnology have in circulation?
The max supply of Puma Biotechnology shares is 51.62M.
What is Puma Biotechnology Price to Earnings Ratio (PE Ratio)?
Puma Biotechnology PE Ratio is 18.11764700 now.
What was Puma Biotechnology earnings per share over the trailing 12 months (TTM)?
Puma Biotechnology EPS is 0.51 USD over the trailing 12 months.
Which sector does the Puma Biotechnology company belong to?
The Puma Biotechnology sector is Healthcare.
Puma Biotechnology PBYI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26180.46 USD — |
+0.43
|
6.32B USD — | 26049.3 USD — | 26269.85 USD — | — - | 6.32B USD — |
|
Dow Jones U.S. Biotechnology In
DJUSBT
US
|
3687.92 USD — |
+1.32
|
166.76M USD — | 3631.54 USD — | 3704.74 USD — | — - | 166.76M USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12848.65 USD — |
+0.42
|
— — | 12783.89 USD — | 12893.08 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7285.19 USD — |
+1.34
|
— — | 7209.03 USD — | 7347.6 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1367.82 USD — |
+1.36
|
— — | 1351.7 USD — | 1374.29 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}
